SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " cancer " 1,727 found 🔀 AI-powered Shuffle
Vikas Sehdev: Starting a New Chapter as Senior Medical Science Liaison at BioNTech SE
Vikas Sehdev: Starting a New Chapter as Senior Medical Science Liaison at BioNTech SE / AstraZeneca, BioNTech SE, cancer, OncoDaily, Oncology, Vikas Sehdev
Tung-Sung Tseng: Honored to Receive the Team Science Champion Award for Tobacco-Related Cancer Research
Tung-Sung Tseng: Honored to Receive the Team Science Champion Award for Tobacco-Related Cancer Research / cancer, LTCI, OncoDaily, Oncology, Team Science
The sky is not falling. Americans are getting healthier.
Despite declining obesity and heart disease rates, increasing cancer survival rates, and a record high life expectancy, politicians from both parties are pushing costly and ineffective policies to …
The fittest founder in the room got cancer. Here's how he used AI to fight back.
When confronted with cancer, Connor Christou fed everything tied tied to his regime — blood results, scan data, wearable output, journal entries — into Claude.
New vitamin B12 therapy shows promise against deadly brain cancer
Researchers have identified a vitamin B12–based compound that can cross the blood-brain barrier and home in on glioblastoma tumors. In animal studies, the compound accumulated preferentially in tumor tissue and delivered sustained nitric oxide directly to cancer cells. It also worked synergistically with existing glioblastoma treatments, significantly enhancing their tumor-fighting effects.
Burglars steal from Grand Forks business, cancer fundraiser
The owner of An Elegant Affair says burglars stole merchandise, cash and donations collected for an employee battling cancer.
AI-assisted colonoscopy enhances polyp detection at UT Health San Antonio Multispecialty and Research Hospital
Contact: Steven Lee, (210) 450-3823, lees22@uthscsa.edu Content provided by Kristen Zapata SAN ANTONIO, June 29, 2026 – A routine colonoscopy may last less than an hour. But what happens during that procedure can change, or even save, a life years before cancer ever has a chance to develop. Physicians at The University of Texas at San […]
Bridget and Mike Chiodo on Strong Bond, Health Struggles, Family
Influencer Bridget Bahl and her husband Dr. Mike Chiodo join TODAY’s Jenna Bush Hager and Sheinelle Jones to celebrate Bridget becoming cancer free, open up about their steadfast bond and share an update on their dream of starting a family.
Andy Cohen cries as he mourns 28-year-old 'WWHL' producer who died of brain cancer
Andy Cohen became emotional mourning 'Watch What Happens Live' production manager Kyra Samson, 28, who died of brain cancer earlier this week.
OHSU advances massive leap in medical science with cellular therapies
Patients are benefiting from CAR-T to treat neurodegenerative diseases, cancer, lupus and other autoimmune conditions.
Supreme Court rules in weedkiller cancer case
Dems want to unmask Eli Lilly's obesity drug user, a new genome-editing tool raises ethics questions, and more health news
Most Patients Want Docs To Break Cancer News Directly, Not Through Portal Messaging
By Dennis Thompson HealthDay ReporterFRIDAY, June 25, 2026 (HealthDay News) — People are becoming more comfortable communicating with their doctor through clinics’ patient portals. Folks use the portals to ask their doc questions and even to review the results of recent medical tests. But there are ...
Bayer wins in US court, but at what cost to public health?
A landmark US Supreme Court ruling protects Bayer from thousands of lawsuits linked to its Roundup weedkiller. Plaintiffs alleged the German agrochemical giant failed to warn users about potential cancer risks.
UT Health San Antonio researcher receives $400,000 Komen grant to study therapeutic yoga for breast cancer survivors
UT Health San Antonio researcher receives $400,000 Komen grant to study therapeutic yoga for breast cancer survivors
UT Health San Antonio researcher receives $400,000 Komen grant to study therapeutic yoga for breast cancer survivors
Amelie G. Ramirez, DrPH, MPH, to work with Hispanics in South Texas Contact: Steven Lee, (210) 450-3823, lees22@uthscsa.edu Content provided by Cliff Despres SAN ANTONIO, June 25, 2026 – Amelie G. Ramirez, DrPH, MPH, a cancer researcher at UT Health San Antonio, the academic health center of The University of Texas at San Antonio, is […]
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
Supreme Court sides with big business in Roundup cancer risk fight
The ruling is also a victory for the Trump administration and a defeat for the Make America Healthy Again movement.
GLP-1 and reduced cancer risk discovery earns UT Health San Antonio fellow prestigious Helio NextGen Disruptor Award
Colton Frisco Jones, MD, a 2nd-year fellow at the Mays Cancer Center at UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio), recently earned the prestigious Healio NextGen Disruptor Award at the American Society of Clinical Oncology (ASCO) 2026 annual meeting in Chicago.
First-of-its-kind discovery earns UT Health San Antonio Mays Cancer Center fellow prestigious Helio NextGen Disruptor Award
Colton Frisco Jones, MD, a 2nd-year fellow at the Mays Cancer Center at UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio), recently earned the prestigious Healio NextGen Disruptor Award at the American Society of Clinical Oncology (ASCO) 2026 annual meeting in Chicago.
Supreme Court sides with big business in Roundup cancer risk fight
The ruling is also a victory for the Trump administration and a defeat for the Make America Healthy Again movement.
Keith Flaherty: Translating Science into Medicine
Keith Flaherty: Translating Science into Medicine / American Association for Cancer Research, cancer, Keith Flaherty, Massachusetts General Hospital,
FDA-approved drug may finally help immunotherapy defeat rare liver cancer
Researchers found that a rare liver cancer evades immunotherapy by luring immune T cells away from the tumor and trapping them in nearby fibrous tissue. An FDA-approved drug called AMD3100 freed those T cells to attack the cancer, significantly improving the effectiveness of immunotherapy in tumor samples.
Bacteria-killing viruses redirect vaccine immunity to destroy cancer
Phages, viruses that infect bacteria, could be genetically manipulated to destroy cancerous cells using the immunity we have acquired from vaccines
Imaging-related burdens may be keeping some from completing cancer screenings
Targeted interventions could help reduce pre-test anxiety, improve the physical screening experience, and address structural barriers in underserved settings.
Tongue Cancer Survivor Reunites with ICU Doctor Who Helped Save Her Life
After a life-threatening complication from tongue cancer surgery led to septic shock and organ failure, high school teacher Jennifer Quick spent nearly a month in the ICU at Atrium Health.
Oklahoma ACA insurer Mending to end health plans after this year
A health policy analyst says the move comes amid a broader trend of insurer exits as several federal policy changes fuel declining enrollment.
As cancer death rates plunge, clear disparities remain, new report says
Black and American Indian/Alaska Native communities have the highest cancer rates of any racial or ethnic group in the U.S.
Bills legend Jim Kelly provides update on condition after stroke
After beating cancer in 2019, Bills legend Jim Kelly revealed that he suffered a setback while recovering from a spring stroke.
Meet the doctor building tiny tools for big science breakthroughs
UCLA's Steven Jonas uses nanotechnology in his lab to explore cancer and other disease-fighting tools.
Vanderbilt Health lands three of 35 Susan G. Komen research grants
Komen is the largest nonprofit funder of breast cancer research outside of the U.S. government, having invested more than $1.1 billion in research since its founding.
RWJBarnabas Health and Rutgers Cancer Institute Unveil the Melchiorre Cancer Center, Expanding Access to World-Class Cancer Care
Today, RWJBarnabas Health and Rutgers Cancer Institute, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, unveiled the Melchiorre Cancer Center at Cooperman Barnabas Medical Center.
Johnson County cancer survivor's business helping others got her two tickets to the World Cup
The Balm Box include items like blankets, underarm pillows, cuticle oil, and lip balm — products designed to address the real side effects of cancer treatment.
New framework renders AI trustworthy for cancer subtyping
The framework, reported in Nature Biomedical Engineering, is broadly adaptable as a wrapper for digital pathology AI systems.
How This Common Painkiller Is Stopping Cancer From Spreading, Scientists Reveal - Futura-Sciences
Guess Who? The Painkiller Hiding a Secret Weapon Riddle: it’s in countless family medicine cabinets. It’s the go-to when fever or pain strikes. For more than half a century, scientists have known about its anticancer properties. Some even believe it might lower the risk of metastases—those are the little troublemakers...
National Family Planning & Reproductive Health Association et al. v. Robert F. Kennedy, Jr. et al.
The National Family Planning & Reproductive Health Association (NFPRHA) and its member, the Family Health Council of Central Pennsylvania (FHCCP), sued the Trump administration to protect the integrity of the Title X family planning program. Title X is the country’s only dedicated federal program for family planning services. For more than 55 years, the program has provided access to effective contraceptive methods, cancer screenings, testing and treatment for STIs, and other preventive services, with priority given to patients with low incomes.
UWF professor secures $825,000 grant to support cancer survivors - University of West Florida Newsroom
University of West Florida Assistant Professor of Public Health Dr. Karishma Chhabria Unrue has been awarded a nearly $825,000 grant through the Florida Cancer Innovation Fund to lead a statewide initiative focused on improving the health and well-being of breast and prostate cancer survivors. The award represents one of the largest externally funded research grants […]
University of Hawaiʻi researchers awarded $12M grant to advance AI, data science in medicine
The funding will be dedicated to accelerating biomedical discoveries through AI and data science to benefit people in Hawaiʻi and the Pacific region, and worldwide.
A common vitamin could help fight one of the deadliest brain cancers
A clinical trial is exploring whether high doses of vitamin B3 could give patients with glioblastoma a better chance against the aggressive brain cancer. Scientists found that niacin may help revive immune cells that tumors shut down, allowing them to attack cancer more effectively. Early results have been promising, with patients showing significantly better progression-free survival than expected.
Long-term health risks of e-cigarettes after smoking cessation
Nature Medicine - Real‑world evidence from a nationwide cohort suggests that using electronic cigarettes after smoking cessation may attenuate the benefits of quitting in reducing lung cancer...
Construction starts on 7th Highlands Oncology Center
Springdale-based cancer-care provider Highlands Oncology recently broke ground on a five-story, 125,000-square-foot cancer-care center along Interstate 49 in the Pinnacle Hills area of Rogers. The Rogers Cancer Center at 4872...
There are higher colon cancer rates among people of Cajun descent. Here’s what doctors are doing to help.
Learn about the significance of colonoscopies in detecting and preventing colon cancer, especially in high-risk populations like the Cajun community in Louisiana. Early screenings can save lives and improve outcomes.
Jeremy Clarkson in remission from prostate cancer
The 66-year-old announced the positive news days after he shared his "aggressive" cancer diagnosis.
UH researchers awarded $12M grant to advance AI, data science in medicine | University of Hawaiʻi System News
New center will support innovative biomedical research, develop future scientific leaders, and expand research infrastructure in Hawaiʻi.
Major review finds vaping likely causes lung and oral cancer
Researchers have concluded that nicotine vapes are likely to cause lung and oral cancers, based on evidence ranging from human biomarkers to animal and laboratory studies. The findings challenge the idea that vaping is a harmless alternative to smoking and suggest health risks may be emerging much sooner than many expected.
'The Pitt' star Katherine LaNasa on Dana's emotional breakdown over sexual assault survivor
Katherine LaNasa explains how her own battle with cancer and ex-husband Dennis Hopper's death informs her work on 'The Pitt' — and why her character had an emotional breakdown over a sexual assault survivor.
Hoops for Health first public event for the WOW vehicle
Wellness on Wheels, the 34-foot mobile health unit that was first unveiled earlier this month, provided free prostate cancer screenings, blood pressure checks, health education and information on county health programs.
This DNA repair gene went rogue and exposed a cancer weakness
Scientists have discovered that a gene normally considered a DNA-protecting "good guy" can become dangerous when cells make too much of it. The gene, EXO1, acts like molecular scissors that help repair DNA, but when overproduced it starts cutting DNA it shouldn't, creating damage linked to cancer.
Should everyone be on GLP-1s? What science actually tells us (and doesn't) about the broader health benefits
The laundry list of possible health benefits from GLP-1 drugs seems to get longer by the day, from cancer prevention to combating addiction. But while there’s no question these medications show immense promise beyond their use for diabetes and weight loss, science is still catching up.
Scott Lowe, researcher: ‘Governments must fund science. Pharmaceutical companies want to help, but they also want to make money’
The geneticist speaks with EL PAÍS about the advances and challenges in the field of cancer research
Cancer patients at Emplify Health by Gundersen receive blankets
This is the 17th year of Dahl Subaru’s and Emplify Health’s blankets event.
Conservatives are dying at higher rates than liberals. A new study points to mistrust in medicine
The health divide emerged over the last decade and has widened since 2020, according to research that links ideology to outcomes from heart disease, cancer, stroke, and other internal causes.
Scientists are uncovering how common viruses may quietly increase cancer risk
Everyday viral infections may be quietly reshaping the body’s network of molecules that support cells and tissues in ways that can raise cancer risk over time
South Florida’s heat makes cancer patients sicker and more isolated, study says
One cancer survivor told researchers the sun “sucks the life out of him.”
The unwanted return of tetanus; why soccer makes people so happy; breast cancer in men; plus other stories with Vanderbilt Health sources
Women’s Health interviewed Kathryn Edwards, MD, Sarah H. Sell and Cornelius Vanderbilt Professor of Pediatrics, for a story about her JAMA Viewpoint article on tetanus making a comeback. Women’s Health interviewed Colin Armstrong, PhD, Assistant Professor of Clinical Psychiatry and Behavioral Sciences and Assistant Professor of Physical Medicine and Rehabilitation, for a story tied to the World Cup about why soccer makes people so happy. An NBC News story about the announcement by “X-Men” actor and former wrestler Tyler Mane that he has breast cancer quotes Ben Ho Park, MD, director of the Vanderbilt-Ingram Cancer Center. The story focuses on how a prominent man with breast cancer may help remove some stigma from a cancer that is rare in males. Prevention magazine interviewed Caitlyn Mooney, MD, Assistant Professor, Department of Orthopaedic Surgery, for a story about a BMJ study that suggests 90 to 120 minutes per week of strength training may lower the risk of death. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: Women’s Health (norovirus is more common this summer); SFGate (measles in San Francisco just before the World Cup crowds); Travel + Leisure (how to avoid getting sick on a cruise); and Fox News (mosquito-borne diseases). Reporter Liz DeSantis from WKRN News 2 aired a story on the rehab unit at Monroe Carell Jr. Children’s Hospital at Vanderbilt. Kat Hedden, PT, DPT, PCS, CBIS, Acute Pediatric Physical Therapy Clinical Team Lead and Mary McLanahan, MD, Assistant Professor of Physical Medicine and Rehabilitation were interviewed, as well as the family of patient Will Terry. Reporter Nikki Hauser from WTVF News Channel 5 interviewed Graden Knapp, Gaming and Technology Specialist at Monroe Carell Jr. Children’s Hospital at Vanderbilt about his 3-D wheelchair project. Tennesseanreporter Sandy Mazza covered the announcement of the latest Leadership Nashville class, which includes Jane Freedman, MD, Deputy CEO, and Chief Health Systems Office for Vanderbilt Health; and also the announcement of the latest Leadership Tennessee cohort, which includes Jeff Upperman, MD, Surgeon in Chief at Monroe Carroll Jr Children’s Hospital at Vanderbilt.
SC Lowcountry student enjoys summer shaped by science
St. Baldrick's fellowship gives College of Charleston student time and support to take on pediatric cancer research
Trump changes pregnancy-prevention program to promote childbearing
A federal poverty-fighting program focused on reducing unintended pregnancies is about to undergo a major overhaul. Reproductive health clinics use Title X federal grant money to provide birth control, cancer screenings and testing and treatment for sexually transmitted infections to people with little or no health insurance. Title X money cannot be used for abortions. The […]
Scientists Discover Reason Some Cancer Treatments Stop Working
Dr. André Veillette told Newsweek that their findings could help patients who do not respond to current cancer treatments.
'Top Gear' star Jeremy Clarkson reveals 'aggressive' cancer diagnosis after health scares
Jeremy Clarkson reveals he is battling aggressive but early-stage prostate cancer in the final two episodes of "Clarkson's Farm" season five.
Allegheny Health Network helps cancer patients know they're not alone
When you hear you're diagnosed with cancer, it can be overwhelming. It can leave questions, anger and a feeling of seclusion.
UF Health Cancer Institute Hosts Conference for Science Teachers
Science teachers from across Florida and the southeastern United States gathered in Gainesville this week for the UF Health Cancer Institute’s Cancer Research Conference for Science Teachers.
Penn State Health raises $51,742 during second annual ‘Let’s Get Ahead’ campaign
Penn State Health raised $51,742 through its second annual “Let’s Get Ahead” campaign during Head and Neck Cancer Awareness Month in April.
Lore'l from The Morning Hustle has entertainment headlines
Zendaya and Tom Holland could be married, Deion Sanders says he's cancer-free and watch out for fake online stores
Jeremy Clarkson, ex-’Top Gear’ host, says he has ‘aggressive’ cancer
(CNN) — Jeremy Clarkson has announced that he has been diagnosed with an “aggressive” form of cancer.
Jeremy Clarkson reveals ‘aggressive’ prostate cancer diagnosis during ‘Clarkson’s Farm’ episode
The British television presenter said the disease had been found early.
Early-Onset Cancers Are On The Rise. Knowing Your Family History Is Crucial.
By Cara Anthony and Blake Farmer - Nashville Public Radio and KFF Health News HealthDay ReportersWEDNESDAY, June 17, 2026 (HealthDay News) — Bryce Ramsey of Madison, Mississippi, was 33 when she was diagnosed with colorectal cancer. Upon noticing blood in her stool, she blamed the hemorrhoids she’d developed after delivering her son eight years earlier. Ramsey didn’t initially link her symptoms ...
He fled Iran for the American dream, became a millionaire, and could have retired—instead, he built the health tech that saved his father from cancer
Health tech millionaire escaped Iran with nothing—now he skips lunch, spends $500 a month on carrot juice, and bought his whole team Rolexes.
Deion Sanders' Son Ready To Get His Health Checked After Cancer Survivor Father's New Initiative
Deion Sanders’ health scare began with a routine scan, the kind that most men would rather delay. Fortunately, it caught his bladder cancer early, and now the Colorado head coach is trying to push that lesson onto other men, starting with his eldest son.
Overcoming Taboos: Helping Men with Cancer Restore Sexual Health
Nearly half of men treated for cancer – as well as up to 90% of those treated for prostate cancer – experience erectile challenges or other sexual dysfunction, but the issue is often not raised in the doctor’s office.
These 36 Scientists Are Leading the Way to Biomedical Discoveries
On June 16, Pew announced the 2026 class of Pew Scholars Program in the Biomedical Sciences, Pew Latin American Fellows Program in the Biomedical Sciences, and Pew-Stewart Scholars Program for Cancer Research. These researchers will receive multiyear grants and join a community of more than 1,000 scientists who are taking creative approaches to cancer biology, neuroscience, immunology, and more.
Autonomous labs are running science experiments 24/7
Robots and AI are running experiments around the clock, from battery chemistry to cancer therapies. But can they be trusted to get it right?
SkinVision Pro Launches Globally at HLTH Europe: AI-powered Skin Health Platform Connected To Healthcare Providers
SkinVision today launched SkinVision Pro, a platform that connects medical practices directly to the SkinVision Service, an AI-powered solution that provides a risk indication for skin spots. The announcement was made at HLTH Europe, responding to growing demand from medical practices seeking to integrate skin assessment results into their clinical workflow. The launch comes as skin cancer incidence has tripled over the past two decades, dermatology wait times reach up to six months in many heal
A 'Useless' Organ That Doctors Often Remove May Actually Fight Cancer
You may not even know you have one.
Two Women, One Mission: Closing the Gap Between Cancer Science and Survival
A journalist-turned-advocate and a physician-scientist unite at the Parker Institute for Cancer Immunotherapy to accelerate cancer vaccines from lab discovery to lifesaving treatment.
Katie Thurston Delays Biopsy, New Treatment for Stage 4 Breast Cancer for 'Mental Health Reasons’: ‘I Need a Break’
Katie Thurston has been open about her fear of needles and the emotional toll of her stage 4 breast cancer journey. The ‘Bachelorette’ alum said she’s now pushing back a biopsy and new treatment to prioritize her mental health.
What COVID is teaching doctors about the relationship between viruses and cancer
The pandemic has left some evidence that viral infection may play a role in reawakening dormant cancer cells already present in a patient’s body before infection.
Seth Rogen recalls first day back on 'The Studio' after Catherine O'Hara died: 'We didn't know what to do'
The series star and co-creator said he hoped she would be able to return to the show amid her cancer battle.
NHS staff battling wave of food supplement disinformation
Exclusive: Cancer charity says dispelling falsehoods gleaned from social media is now routine task for clinicians
Dear Abby: My partner has cancer but refuses to acknowledge my health issues
Dear Abby gives advice to a reader whose significant other doesn't seem to care about her health issues as he battles cancer.
GLP-1 Drugs May Protect Against Cancer— Here’s What That Means For Public Health
New research suggests GLP-1 drugs could reduce cancer risk. A doctor breaks down how that could change public health in the future.
Doctor, former cancer patient share stories amid focus on men's health
Doctor and former cancer patient share stories amid focus on men's health
UCLA Health receives significant commitment from longtime children’s health donors Dr. Neal and Beth Cutler to endow a chair and support translational cancer research
UCLA Health receives significant commitment from longtime children’s health donors Dr. Neal and Beth Cutler to endow a chair and support translational cancer research
UT Austin researchers create nanoscale Longhorn using DNA origami
UT Austin researchers folded DNA into a nanoscale Longhorn, demonstrating a breakthrough that could help deliver cancer drugs more precisely and speed up the production of advanced materials.
International experts issue new MRI-based prostate cancer screening guidance
The exam should be performed on patients with greater than 10 years of life expectancy and between the ages of 50 and 70, with earlier imaging recommended for black men.
Cancer dominates PFAS conversations — science points elsewhere
Studies link PFAS exposure to cholesterol, immune function, even bone density — findings that rarely make headlines. The cancer question remains open, and the list of what science is still […]
Community Health in Action: Manor College at the Byrd Cancer Expo
The All Things Cancer + Wellness Expo is designed to provide free access to essential health services, educational resources and community support. Manor College Dental Hygiene students delivered an oral health initiative at the annual Byrd Cancer Foundation Wellness and Cancer Expo on April 18. The entire Dental Hygiene cohort participated to provide over 30 Read more >
Dwayne Johnson on Cancer Scare, Not Talking Politics and Oscar Snub
Dwayne Johnson admits he wishes he got an Oscar nomination for 'The Smashing Machine' and reveals a recent cancer scare.
Scammers hijacked the identity of a famous Oregon cancer doctor to pitch ivermectin online
The bogus accounts – and others like them – alarm doctors worried about how the misinformation can harm unsuspecting patients desperate for help.
The deadly tapeworm spreading across America has reached the Pacific Northwest
A potentially dangerous tapeworm linked to severe, cancer-like disease has now been found in the Pacific Northwest, marking its first detection in wild animals along the U.S. West Coast. Researchers discovered the parasite, Echinococcus multilocularis, in 37% of coyotes tested around Puget Sound—a surprisingly high rate for a region where it had never been reported until recently.
HHS responds coolly to paper on alcohol risk
Soda and liver cancer, scientists conflicted on a new NIH proposal, and more health news from Morning Rounds
Penn study finds GLP-1 use associated with lower breast cancer risk; researchers to launch clinical trial
Women in the study who were obese and taking GLP-1 weight loss medications were 30% less likely to develop breast cancer than other women.
Deion Sanders says he is cancer-free, fully healthy for 2026 season
Deion Sanders says he is cancer-free and fully healthy, crediting early detection after bladder cancer last year.
Artificial turf contains 400 chemicals tied to cancer and hormone disruption. But is it unsafe?
A recent, 10-year study from California identified many known or suspected carcinogens in artificial turf. Does it pose a danger?
Essentia Health-Fargo offers new minimally invasive procedure for uterine fibroids
Essentia Health-Fargo is now offering a minimally invasive, non-hormonal procedure to treat symptomatic uterine fibroids, which are non-cancerous growths in the uterus, offering women a uterine-sparing alternative to hysterectomy.
New OMB rule could break science in the United States
The drug that saved your mother. The treatment your doctor recommended. The clinical trial that bought someone you love more time. None of it was inevitable. It required a system built to operate outside politics and sustained over decades, because science doesn’t operate on the timeline of a politician. That system is now under direct threat. The Office of Management and Budget (OMB) has proposed a new rule to regulate all federal grants, not just science, but housing, education, defense, NASA and everything in between, that would fundamentally change how research is conducted in the United States. There have been a lot of fires in the past 16 months, and if everything is an emergency, nothing is an emergency. But this is a very big deal. These rules would strip away the independence that has kept science from becoming a political tool. The good news is there’s still something we can all do. How the grant system was designed to work When I was a new faculty member, I was full of millions of ideas, so I sat down and wrote an NIH proposal. I worked on it for months and thought it was so good. Then I sent it to my mentor. It came back covered in comments. Places where my reasoning wasn’t as airtight as I’d thought, methods that could be stronger, gaps in my thinking that I had been too close to the work to see. It stung, as honest feedback always does, but peer review almost always makes the work better. In fact, it’s the backbone of how American science has functioned for generations. At NIH, submitted proposals go to a panel of scientists who have experience in the field. These are the people who can read research methods and spot their weaknesses, who understand when an experiment is designed well and when it isn’t. Applications are scored rigorously, and often only the top 3-20% of proposals receive funding. The people making funding decisions are required to justify them based on these reviews. To be clear: this is not a perfect system, and good science still goes unfunded more often than any of us would like due to limited resources. There is also criticism that peer review may undervalue bold ideas that are risky but could have high payoffs. But the peer review system is nonetheless a meaningful part of the grant selection process. While thoughtful and careful changes could improve the system, the changes being proposed by OMB will not make things better. The rule that could change everything Through this OMB proposal, the system that helps decide what gets funded is being dismantled. There are many troubling elements buried in this proposal, but three provisions stand out in particular. Each would be damaging alone. Together, they would change what kind of science gets done in America, and who it serves. 1. Political appointees would decide which science gets funded, and peer review would be explicitly sidelined or ignored. The guidelines your doctor follows, the standards that determine what’s in your air and water, the drugs that get approved for your family: all of it starts with a funding decision. Right now, that decision is made by scientists who can evaluate whether the work is actually sound and whether it could move the needle forward. Under this proposal, funding decisions could be made by political appointees. The careful, expertise-driven review process that shapes grant funding would be effectively sidelined. That means that a poorly designed study could get funded simply because someone in a political office liked the sound of it, while rigorous, important work doesn’t get funded because it no longer aligns with the administration’s priorities. In other words, critical work that benefits all of us could now be missed just because it has become politically inconvenient. 2. Grants could be canceled at any point, without warning, in the middle of ongoing work. Say your tax dollars have been paying for a cancer study for two years. The grant was awarded for five years, so the team is mid-experiment. There are three additional years’ worth of answers that could change how the disease is treated for hundreds of thousands of people. With this new rule, the federal government could cancel the remaining funding tomorrow, walk away from the commitment it made with your money, and have no legal obligation to finish what it started. This is a huge waste of money. There are rarely other sources of funding for this work, which means the team, the graduate students, postdocs, and research staff who have dedicated years of their careers to this project could lose their jobs. Patients who have contributed their time to studies may not see it turn into useful learnings for others. Every hour of work already completed could result in nothing useful. Science can take decades to get to tangible outcomes. It needs a stable funding system to flourish. 3. Researchers would have a harder time communicating their findings without pre-approval from the federal government. There is a saying from Sir Mark Walport: “Science isn’t finished until it’s communicated.” Science is no use to anyone if it is kept locked away in the labs that produced the data. The proposed rule could make communicating research findings harder in a number of ways: Make it harder for scientists to widely share their findings in scientific journals. Publication costs, including journal fees that allow for broad public access, could not be paid for by federal funds which is often how scientists pay these costs. Restrict researchers from engaging publicly about how their findings should inform policy or public health guidelines. This would restrict scientists from doing the work that transforms years of lab work into decisions that actually affect people’s lives. Make it harder for scientists to attend conferences. Conferences would now need to be approved by the federal agency at the time of grant award. This disadvantages conferences or publications that are not politically aligned. Conferences are a key way in which scientists learn about work happening in their field so they can collaborate and build on each other’s findings. What good is science with a muzzle? The long-term impact These changes could (and hopefully would) be reversed under the next administration. But by then, damage has been done. Once projects are halted or denied funding by political appointees, people leave their science careers for other paths or even leave the country to do their amazing science elsewhere. You cannot pause a scientific study the way you pause a subscription you decided isn’t useful anymore. You cannot freeze a research team that depends on salaries to feed their families, causing a scramble for replacement funding that, in most cases, simply does not exist. When the money stops, everything stops, and all the work in progress and its potential are lost. Despite all of the language about reducing waste, fraud, and abuse, this new proposed rule increases the administrative burden tremendously. Every researcher watching this unfold will make a rational decision: don’t start anything that will take a decade to finish. This includes not building a team around funding that could vanish, or asking the big questions that need patience and stability to answer. The most consequential science, the kind that produces the treatments and the breakthroughs that reach your doctor’s office twenty years from now, is exactly the science that would be abandoned first. This is still a proposal, so we can all do something Some worry this rule is already a done deal. But by law, OMB is required to open a public comment period. Those comments matter because they inform members of Congress, they can be used in litigation, and they create a public record. So here’s what you can do: Submit a public comment. The public comment period on this proposed change is open until July 13. Anyone can submit a comment, and OMB is required to respond to substantial ones. Each comment must be different to count as distinct; identical comments will be counted only once. Comment as an individual, not on behalf of your organization. Here’s a full resource to help you, with useful examples, but in general: Share a story about how science or federal funding has benefitted you or is involved in your work. Are you or someone you loved a cancer survivor? Do you know someone with Alzheimer’s? Have you received NIH/NSF or other federal funding? All of these can be stories you use to highlight why you care. Explain why you’re worried about these proposed changes. You can use the wording found here or in other resources to help you. Ask them to withdraw this proposed rule. Contact your elected representatives. Congress allocates money to federal agencies to spend, and it has oversight of how that process works. You can let your representatives know this proposed change concerns you and ask them to intervene. There are levers they can push that can help at this moment. Let others know why federal funding matters. This isn’t just about science, but ALL federal grants, including for education systems, defense projects, and more. The process, including the importance of federal funding, is invisible to many. We can all make it more visible by sharing how science benefits us and why we value it. You can also share this article, or any of the resources linked here, to help spread awareness! Bottom line We are quickly losing ground in scientific research in the U.S. More changes, like the proposed rule by OMB, would decimate our ability to conduct research here, leaving us all worse off: fewer treatments for pancreatic cancer, less research on pollution impacts, fewer answers for patients with rare disease, and more unaddressed health needs. The impact will be very real for all of us, regardless of where we stand politically. Using our voices for science is more important than ever. Love, LM Big thanks to Dr. Megan Ranney for reading this over and providing brilliant insights, as always. Dr. Liz Marnik, PhD, is Executive Director of The Evidence Collective at YLE and a science communicator and immunologist working at the intersection of public trust, science, and public health. You can find her on Substack, LinkedIn, Instagram and Threads. Your Local Epidemiologist (YLE) comprises a team of experts, ranging from physicians to immunologists to epidemiologists to nutritionists, working together with one goal: to “Translate” ever-evolving public health science so that people are well-equipped to make evidence-based decisions. The YLE suite of newsletters reaches over 475,000 people across more than 132 countries. This newsletter is free to everyone, thanks to the generous support of fellow YLE community members. To support the effort, subscribe or upgrade below: Subscribe
Baton Rouge General's Health Tip of the Week: How health overconfidence is hurting men
Sponsored by Baton Rouge General A recent poll found that 65% of men believe they’re healthier than other men. Statistically, that can’t be true, but it may explain why so many skip preventive care. The reality is that conditions like high blood pressure, diabetes, heart disease, and some cancers can develop without obvious symptoms. That’s […]
UT Health San Antonio awarded grant to advance cervical cancer screening
Content provided by Lauren Michalk UT Health San Antonio has been selected as a recipient of the American Cancer Society’s Self-Collected Human Papillomavirus Readiness Pilot (SHaRP) grant, a national initiative designed to help health care organizations prepare for and implement HPV self-collection as part of routine cervical cancer screening. SHaRP supports the integration of human papillomavirus […]
UT Health San Antonio awarded American Cancer Society SHaRP grant to advance cervical cancer screening
Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu Content provided by Lauren Michalk SAN ANTONIO, June 9, 2026 – UT Health San Antonio has been selected as a recipient of the American Cancer Society’s Self-Collected Human Papillomavirus Readiness Pilot (SHaRP) grant, a national initiative designed to help health care organizations prepare for and implement HPV self-collection as part […]
More Americans survive cancer. But the psychological impacts can persist for years
Due to advancements in treatment and screening, more Americans are surviving cancer. But many are left with lingering mental health challenges like anxiety and depression.
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are currently under review by the FDA for approval this year.
Resistance Training Appears to Restore Physical Strength, Immune Health in Frail or At-Risk Cancer Survivors
10-week exercise program erased signs of chronic inflammation caused by chemotherapy and radiation